eli lilly and company zepbound

Eli Lilly, weight loss

Eli Lilly CEO expects new weight loss pill to be approved next year

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.

Investopedia on MSN · 19h

S&P 500 Gains and Losses Today: Eli Lilly Stock Falls as Sales Outlook Weakens

The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead of Wednesday's consumer price report.

Business Insider · 1d

Eli Lilly CEO tells Bloomberg TV company sees weight loss pill approval in 2026

Eli Lilly (LLY) expects that its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks said in an

Lilly shares on track for worst day since 2021

BioSpace · 19h

Lilly Projects 2024 Revenue Miss as Zepbound, Mounjaro Disappoint

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, sent Eli Lilly’s shares cratering by as much as 8% Tuesday, even as the company forecasted robust 2025 revenue.

MarketWatch · 19h

Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts

Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter revenue guidance that was below Wall Street expectations,

Reuters · 22h

Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed since the drug's launch in late 2023.

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

STAT1d

Eli Lilly’s stock falls after 2024 guidance misses forecasts

Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales ...

14hon MSN

Watch These Eli Lilly Price Levels as Stock Slumps on Tepid Sales Outlook

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...

6don MSN

Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

6hon MSN

These Stocks Are Moving the Most Today: JPMorgan, Wells Fargo, Eli Lilly, D-Wave Quantum, and More

JPMorgan Chase, Wells Fargo, Goldman Sachs, and Citigroup are scheduled to report fourth-quarter earnings Wednesday.

FiercePharma17h

JPM25: Eli Lilly's preliminary '24 sales figures show a continued easing in breakneck GLP-1 market

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Eli Lilly Q4 miss brings buying opportunity, says JPMorgan

JPMorgan analyst Chris Schott says Eli Lilly’s Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidanc ...

Hosted on MSN1d

These Stocks Are Moving the Most Today: Palantir, Nvidia, Eli Lilly, KB Home, Signet, Applied Digital, Aehr, and More

Eli Lilly declined 7% after the pharmaceutical company reported sales of blockbuster GLP-1 medicines Zepbound and ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results